You are here: Industry Insights > Allogene Therapeutics

News List

Allogene Therapeutics to build out facility for allogeneic CAR T treatments fiercepharma
February 24, 2019
Another CAR T production facility is slated for the U.S. as a biotech moves down the road with a bucket full of cash and a fist full of candidates. But unlike currently approved CAR T treatments, Allogene Therapeutics is looking to use donated T cells tha
Ablexis Announces Licensing Agreement with Allogene Therapeutics americanpharmaceuticalreview
December 10, 2018
Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, has announced a license agreement....
Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting firstwordpharma
December 04, 2018
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced results of a preclinical study of ALLO-715, an AlloCAR T therapy targeting
Pfizer, Allogene Therapeutics Enter into Asset Contribution Agreement americanpharmaceuticalreview
April 09, 2018
Pfizer and Heterologous Therapeutics Announce the Agreement between Pfizer and Allo-Chimeric Antigen Receptor T Cell (CAR T) Treatment Related Assets